Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS)

Lower urinary tract symptoms (LUTS) and ureteral-stent-related symp-toms (uSRS) are similar to those of lower urinary tract symptoms caused by benign prostatic hypertrophy (BPH), and complaints about urgency and frequency of urination are the same as in patients with overactive bladder syndrome (OAB). β₃-adrenoceptor agonist (Mirabegron) and anti-muscarinic (Solifenacin) therapies used for LUTS and OAB therapy can also be used to reduce SRS complaints. This study aimed to determine the effectiveness of using Solifenacin as a treatment for uSRS as compared to Mirabegron. This study used a double-blinded experimental design. Samples were taken randomly (consecutive random sampling) from fifty patients with uSRS. Data was collected using the Ureteral Symptoms Score Questionnaire (USSQ) as a measuring instrument. Data was analyzed using the mean, t-Test, and Chi-square tests. P values of [J Med Allied Sci 2020; 10(2.000): 115-120]